• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » More Evidence of Lives Saved by Medications for Opioid Use Disorder

More Evidence of Lives Saved by Medications for Opioid Use Disorder

January 1, 2019
Thomas Jordan, MD, MPH
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Thomas Jordan, MD, MPH Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Larochelle MR et al, Ann Intern Med 2018;169(3):137–145

We are in the middle of an opioid crisis in the US, with many lives lost daily to opioid-related deaths. Pharmacotherapy with methadone, buprenorphine, or naltrexone represents an important tool for clinicians during this crisis. But just how good are these medications in saving lives? A recent retrospective cohort study evaluated the effects of methadone, buprenorphine, and naltrexone on all-cause and opioid-related mortality in the 12 months after an opioid overdose.

This analysis used data from Massachusetts government and hospital records from 2012 to 2014 to identify adults who survived an opioid overdose, then looked at the 12 months after that overdose. If an individual had multiple overdoses during that period, the first overdose was used for the data collection. A total of 17,568 cases were identified. In the 12 months after the index overdose, 11% (2,040) were on methadone for a median of 5 months, 17% (3,022) were on buprenorphine for a median of 4 months, and 6% (1,099) were on naltrexone for a median of 1 month.

All-cause mortality over 12 months was significantly reduced in those receiving methadone (adjusted hazard ratio [AHR] 0.47 [CI 0.32–0.71]) and buprenorphine (AHR 0.63 [CI 0.46–0.87]), but not those on naltrexone (AHR 1.44 [CI 0.84–2.46]). Similarly, opioid-related mortality was significantly decreased for patients on methadone (AHR 0.41 [CI 0.24–0.70]) and buprenorphine (AHR 0.62 [CI 0.41–0.92]), but not those on naltrexone (AHR 1.42 [CI 0.73–2.79]).

CATR’s Take
This study represents real-world population data linking treatment with methadone or buprenorphine after an opioid overdose to a decrease in all-cause and opioid-related mortality in the following year. Remember, these results were tallied over a 1-year period even though most patients discontinued treatment within 6 months. Naltrexone failed to show a significant difference in mortality, perhaps because most people stopped it after 1 month, or because the researchers could not distinguish between the oral and extended release injectable formulations (unlike oral naltrexone, extended release naltrexone has shown treatment efficacy). Another takeaway from this article is that only about a third of those who had an opioid overdose were ever prescribed any form of opioid use disorder pharmacotherapy. Much work remains to be done to provide better access to life-saving treatment for opioid use disorder.
Addiction Treatment
KEYWORDS opioids registered-articles research-update
Thomas Jordan, MD, MPH

Managing Substance-Related Agitation

More from this author
www.thecarlatreport.com
Issue Date: January 1, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Board Certification in Addiction Medicine, CATR, January/February 2019
More Evidence of Lives Saved by Medications for Opioid Use Disorder
Coffee: Healthy Study Aid or the Addiction We Hate to Acknowledge?
Becoming a Board-Certified Addiction Clinician
Introducing CRAFT: A Non-Confrontational Intervention We Can Recommend to Families
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.